Colgate Palmolive CL

NYSE CL

$88.38 -0.39 (-0.44%)

As of: Sep 8, 2026 · 3:59 PM EDT

Key Stats

Market Cap70.76 Bn

P/E32.83

P/S3.36

Div. Yield2.58

Total Debt (Qtr)7.86 Bn

Revenue Growth (1y) (Qtr)4.91

Add ratio to table…

About

Colgate-Palmolive Company is a global consumer products company focused on oral care, personal care, home care, and pet nutrition. The company designs, manufactures, and markets essential everyday products used by households worldwide. Its operations span over 200 countries and territories, supported by a portfolio of globally recognized brands. Colgate-Palmolive emphasizes innovation, sustainability, and inclusive growth to meet evolving consumer needs. The company…

The company generates revenue primarily through the sale of its branded consumer products across four key categories: oral care, personal care, home care, and pet nutrition. These products are distributed through retail channels including supermarkets, drugstores, e-commerce platforms, and specialty retailers. Revenue is driven by brand strength, product innovation, and widespread market penetration, with significant contributions from both developed and emerging markets.

The company operates through the following segments: Oral, Personal and Home Care; and Pet Nutrition.

Oral, Personal and Home Care: This segment encompasses a broad range of consumer hygiene and household products. It includes toothpastes, manual toothbrushes, and mouthwashes sold under brands such as Colgate, Darlie, elmex, hello, meridol, Sorriso, and Tom’s of Maine. The segment also features liquid hand soaps, bar soaps, shower gels, deodorants, antiperspirants, skin health products, dishwashing liquids, household cleaners, and fabric conditioners marketed under brands like Palmolive, Protex, Softsoap, Irish Spring, Sanex, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Fluffy and Cuddly.
Pet Nutrition: This segment focuses on specialty food products for dogs and cats. It includes Hill’s Science Diet, known as Hill’s Science Plan in Europe, which provides everyday nutritional support for pets. Hill’s Prescription Diet offers therapeutic formulations to address specific health conditions in dogs and cats. Additionally, the Prime100 brand provides fresh pet food sold through specialty and other retailers in Australia, supporting the segment’s presence in the pet care market.

Colgate-Palmolive holds leading market positions in several core categories, including global leadership in toothpaste and manual toothbrushes, as well as liquid hand soap. The company competes with multinational consumer goods firms and private-label brands, maintaining advantage through strong brand equity, continuous innovation, and a resilient global supply chain. Its investment in science-based product development and data-driven marketing supports differentiation in competitive markets.

The company serves a diverse customer base that includes major retailers such as Walmart, Inc., as well as wholesalers, distributors, and e-commerce platforms worldwide. Pet nutrition products are sold through authorized pet supply retailers, veterinarians, and online channels. Colgate-Palmolive also engages in direct-to-consumer sales for certain products, leveraging digital platforms to reach end users across various demographics and geographies.

Investment Thesis

▲ Bull case

Colgate-Palmolive's emerging markets momentum is poised to deliver sustainable organic growth acceleration despite North American headwinds, as the company's strategic investments in innovation and demand generation are already yielding results in high-potential regions where it holds strong brand equity and scale advantages. Management highlighted that emerging markets drove the majority of Q1 organic sales growth, with Asia Pacific leading the charge due to successful interventions in the Hawley & Hazel business and strong performance from the Colgate core business in China, which delivered mid-single-digit growth in a flat-to-declining market. This performance is significant because it demonstrates the effectiveness of Colgate's localized strategies, such as accelerated innovation at lower price points and omnichannel execution via platforms like Douyin, which are not only gaining traction but are expected to scale across the organization. Furthermore, Latin America's mid-single-digit growth, fueled by best-in-class RGM and AI-driven demand generation, alongside Africa, Middle East, and Europe outperforming expectations despite pricing actions, underscores the broad-based nature of this strength. The company's confidence in sustaining this momentum is rooted in its view that emerging markets are accretive to long-term growth prospects, and it is actively allocating resources accordingly, which positions it to capture category share as these markets continue to expand and consumers trade up to premium offerings over time.
The expanded Strategic Growth and Productivity Program (SGPP) represents a structural, multi-year catalyst for margin expansion and EPS growth that the market is underestimating, as it goes beyond cost-cutting to fund growth investments while enhancing organizational agility in an omnichannel environment. With the SGPP now targeting $350 million to $550 million in cumulative pretax charges and $200 million to $300 million in annual savings once fully implemented—primarily flowing through in 2027 and 2028—management emphasized that these savings will be deployed to fund incremental investments behind the 2030 strategy and drive consistent compounded dollar-based EPS growth. Crucially, the program's focus on reducing complexity through spans and layers optimization is designed to create a more agile operating model, which is particularly valuable as Colgate navigates volatile input costs and shifting consumer behaviors. This dual benefit—funding growth while improving efficiency—was highlighted as a key reason for the board's approval of the expansion, and it suggests that Colgate is building a self-funding mechanism for long-term value creation that is not yet fully reflected in current valuations, especially given the company's track record of exceeding initial SGPP targets through better-than-expected execution on the ground.
Hill's Pet Nutrition is emerging as a stealth growth engine with durable competitive advantages that are being overlooked amid broader pet category challenges, as its science-backed innovation and strong veterinary endorsement provide pricing power and insulation from macroeconomic pressures. Despite the dry dog segment facing headwinds, Hill's delivered solid organic growth of 4.8% ex-private label in Q1, with the U.S. business growing at 5% and outperforming a roughly flat market, driven by double-digit growth in key areas like Prescription Diet and Science Diet. Management stressed that the brand's super-premium positioning, supported by vet-recommended efficacy, allows it to justify price points even in inflationary environments, and the business is gaining share across nearly all channels through innovations like those in the Small Paws and cat segments. This is significant because Hill's operates in a defensive, necessity-driven category where pet owners prioritize health outcomes over cost, making it less susceptible to discretionary spending cuts. Furthermore, the supply chain's exceptional performance provides flexibility to leverage growth opportunities, and with the category expected to rebound over time, Hill's is well-positioned to accelerate as under-indexed segments like wet food and cat continue to show strong traction, offering a long-term runway for margin-accretive expansion that is not yet priced into the stock.

Colgate-Palmolive's emerging markets momentum is poised to deliver sustainable organic growth acceleration despite North American headwinds, as the company's strategic investments in innovation and demand generation are already yielding results in high-potential regions where it holds strong brand equity and scale advantages. Management highlighted that emerging markets drove the majority of Q1 organic sales growth, with Asia Pacific leading the charge due to successful interventions in the Hawley & Hazel business and strong performance from the Colgate core business in China, which delivered mid-single-digit growth in a flat-to-declining market. This performance is significant because it demonstrates the effectiveness of Colgate's localized strategies, such as accelerated innovation at lower price points and omnichannel execution via platforms like Douyin, which are not only gaining traction but are expected to scale across the organization. Furthermore, Latin America's mid-single-digit growth, fueled by best-in-class RGM and AI-driven demand generation, alongside Africa, Middle East, and Europe outperforming expectations despite pricing actions, underscores the broad-based nature of this strength. The company's confidence in sustaining this momentum is rooted in its view that emerging markets are accretive to long-term growth prospects, and it is actively allocating resources accordingly, which positions it to capture category share as these markets continue to expand and consumers trade up to premium offerings over time.
The expanded Strategic Growth and Productivity Program (SGPP) represents a structural, multi-year catalyst for margin expansion and EPS growth that the market is underestimating, as it goes beyond cost-cutting to fund growth investments while enhancing organizational agility in an omnichannel environment. With the SGPP now targeting $350 million to $550 million in cumulative pretax charges and $200 million to $300 million in annual savings once fully implemented—primarily flowing through in 2027 and 2028—management emphasized that these savings will be deployed to fund incremental investments behind the 2030 strategy and drive consistent compounded dollar-based EPS growth. Crucially, the program's focus on reducing complexity through spans and layers optimization is designed to create a more agile operating model, which is particularly valuable as Colgate navigates volatile input costs and shifting consumer behaviors. This dual benefit—funding growth while improving efficiency—was highlighted as a key reason for the board's approval of the expansion, and it suggests that Colgate is building a self-funding mechanism for long-term value creation that is not yet fully reflected in current valuations, especially given the company's track record of exceeding initial SGPP targets through better-than-expected execution on the ground.
Hill's Pet Nutrition is emerging as a stealth growth engine with durable competitive advantages that are being overlooked amid broader pet category challenges, as its science-backed innovation and strong veterinary endorsement provide pricing power and insulation from macroeconomic pressures. Despite the dry dog segment facing headwinds, Hill's delivered solid organic growth of 4.8% ex-private label in Q1, with the U.S. business growing at 5% and outperforming a roughly flat market, driven by double-digit growth in key areas like Prescription Diet and Science Diet. Management stressed that the brand's super-premium positioning, supported by vet-recommended efficacy, allows it to justify price points even in inflationary environments, and the business is gaining share across nearly all channels through innovations like those in the Small Paws and cat segments. This is significant because Hill's operates in a defensive, necessity-driven category where pet owners prioritize health outcomes over cost, making it less susceptible to discretionary spending cuts. Furthermore, the supply chain's exceptional performance provides flexibility to leverage growth opportunities, and with the category expected to rebound over time, Hill's is well-positioned to accelerate as under-indexed segments like wet food and cat continue to show strong traction, offering a long-term runway for margin-accretive expansion that is not yet priced into the stock.

▼ Bear case

Colgate-Palmolive's North America segment faces persistent structural challenges that are unlikely to resolve quickly, as evidenced by ongoing volume declines and margin pressure that management acknowledged would take time to fix, despite interventions being in place. The segment reported a 3.2% drop in as-reported volume and a 2.2% decline in organic volume in Q1, with operating profit falling 28% year-over-year and margins pressured by tariffs and higher raw material costs. While leadership cited shelf reset delays and later product shipments as temporary factors, the admission that North America would take "some time" to improve, combined with the need for a "strategy reset" involving real brand interventions, accelerated innovation, and RGM adjustments, suggests deeper issues related to market share loss to private label and competitors increasing couponing activity. This is particularly concerning given that North America remains a significant portion of the business (17% of sales), and the company's reliance on emerging markets to offset weakness here creates vulnerability if those regions experience slower-than-expected growth or if currency fluctuations reverse their current tailwinds, which contributed 9.5% to Latin America's growth and 8.5% to EMEA's.
The company's gross margin guidance reflects significant and persistent cost inflation pressures that may not be fully offsettable through RGM and productivity initiatives alone, posing a risk to EPS achievement even if sales targets are met. Management explicitly built in an additional $300 million in raw material and logistics costs for the year, assuming oil at approximately $110, and noted that logistics costs are up nearly 10% impacting both ocean and land freight, with the biggest impact coming from oil byproducts like resins and petrochemicals, which are expected to be up more than 20% year-on-year. Although they cited RGM productivity and the SGPP as offsets, the CFO acknowledged that the logistics component flows into SG&A, not gross margin, meaning only part of the cost burden is mitigated through the cited levers. Furthermore, the warning that gross margin would be "more pressured" for the year, combined with the admission that they are "waiting to see" how consumers respond to pricing in a volatile environment, suggests that pricing power may be limited, especially in value-conscious segments, and that the company may not be able to fully pass on costs without risking volume erosion, which could undermine the bottom line despite top-line growth.
Hill's Pet Nutrition's growth momentum is vulnerable to macroeconomic shifts, particularly sustained high energy prices affecting pet ownership decisions and discretionary spending on premium pet food, which could undermine the segment's resilience and slow its long-term trajectory. While management highlighted Hill's strong performance in Prescription Diet and Science Diet, they also acknowledged that the business is not immune to compounding inflation and that higher gas prices could influence consumers' decisions about trading up or adopting pets, directly impacting demand for super-premium offerings. This is a material risk because Hill's operates at the premium end of the pet nutrition market, where purchasing decisions are more discretionary and sensitive to household budgets, despite the veterinary endorsement. The admission that they would have to "watch that very carefully" regarding inflationary concerns, coupled with the reliance on science-based innovation to justify premium pricing, suggests that any prolonged economic downturn or reduction in veterinary visits could disproportionately affect Hill's, especially if consumers shift to more affordable alternatives or delay non-essential pet care, thereby eroding the segment's growth advantage and increasing pressure on the overall portfolio to compensate.

Colgate-Palmolive's North America segment faces persistent structural challenges that are unlikely to resolve quickly, as evidenced by ongoing volume declines and margin pressure that management acknowledged would take time to fix, despite interventions being in place. The segment reported a 3.2% drop in as-reported volume and a 2.2% decline in organic volume in Q1, with operating profit falling 28% year-over-year and margins pressured by tariffs and higher raw material costs. While leadership cited shelf reset delays and later product shipments as temporary factors, the admission that North America would take "some time" to improve, combined with the need for a "strategy reset" involving real brand interventions, accelerated innovation, and RGM adjustments, suggests deeper issues related to market share loss to private label and competitors increasing couponing activity. This is particularly concerning given that North America remains a significant portion of the business (17% of sales), and the company's reliance on emerging markets to offset weakness here creates vulnerability if those regions experience slower-than-expected growth or if currency fluctuations reverse their current tailwinds, which contributed 9.5% to Latin America's growth and 8.5% to EMEA's.
The company's gross margin guidance reflects significant and persistent cost inflation pressures that may not be fully offsettable through RGM and productivity initiatives alone, posing a risk to EPS achievement even if sales targets are met. Management explicitly built in an additional $300 million in raw material and logistics costs for the year, assuming oil at approximately $110, and noted that logistics costs are up nearly 10% impacting both ocean and land freight, with the biggest impact coming from oil byproducts like resins and petrochemicals, which are expected to be up more than 20% year-on-year. Although they cited RGM productivity and the SGPP as offsets, the CFO acknowledged that the logistics component flows into SG&A, not gross margin, meaning only part of the cost burden is mitigated through the cited levers. Furthermore, the warning that gross margin would be "more pressured" for the year, combined with the admission that they are "waiting to see" how consumers respond to pricing in a volatile environment, suggests that pricing power may be limited, especially in value-conscious segments, and that the company may not be able to fully pass on costs without risking volume erosion, which could undermine the bottom line despite top-line growth.
Hill's Pet Nutrition's growth momentum is vulnerable to macroeconomic shifts, particularly sustained high energy prices affecting pet ownership decisions and discretionary spending on premium pet food, which could undermine the segment's resilience and slow its long-term trajectory. While management highlighted Hill's strong performance in Prescription Diet and Science Diet, they also acknowledged that the business is not immune to compounding inflation and that higher gas prices could influence consumers' decisions about trading up or adopting pets, directly impacting demand for super-premium offerings. This is a material risk because Hill's operates at the premium end of the pet nutrition market, where purchasing decisions are more discretionary and sensitive to household budgets, despite the veterinary endorsement. The admission that they would have to "watch that very carefully" regarding inflationary concerns, coupled with the reliance on science-based innovation to justify premium pricing, suggests that any prolonged economic downturn or reduction in veterinary visits could disproportionately affect Hill's, especially if consumers shift to more affordable alternatives or delay non-essential pet care, thereby eroding the segment's growth advantage and increasing pressure on the overall portfolio to compensate.

Colgate Palmolive CL

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Colgate Palmolive CL

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Create an account

Sign In

Reset Password